Erdheim-Chester disease: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 1-11

  Cives, Mauro ^a   Simone, Valeria ^a   Rizzo, Francesca Maria ^a   Dicuonzo, Franca ^a   Cristallo Lacalamita, Marirosa ^a   Ingravallo, Giuseppe ^a   Silvestris, Franco ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

BRAFV600E; CNS involvement; Erdheim Chester disease; Histiocytosis; Vemurafenib

Indexed keywords

AZATHIOPRINE; B RAF KINASE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; IMATINIB; INFLIXIMAB; INTERFERON; METHOTREXATE; PEGINTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VEMURAFENIB; VINBLASTINE; VINCRISTINE;

ALGORITHM; AORTA DISEASE; ASYMPTOMATIC DISEASE; BONE LESION; BRAF GENE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIABETES INSIPIDUS; ERDHEIM CHESTER DISEASE; EXTRAPYRAMIDAL SYNDROME; GENE CONTROL; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS DISEASE; INCIDENCE; KIDNEY DISEASE; LONG BONE; LUNG DISEASE; NEUROLOGIC DISEASE; ORBIT TUMOR; OSTEOSCLEROSIS; PATHOGENESIS; PROGNOSIS; PYRAMIDAL SIGN; RECURRENT DISEASE; RETROPERITONEAL DISEASE; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; VISUAL DISORDER; ADULT; BONE; CARDIAC MUSCLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; ERDHEIM-CHESTER DISEASE; GENETICS; KIDNEY; MALE; PATHOLOGY; POINT MUTATION;

ADRENAL CORTEX HORMONES; ADULT; BONE AND BONES; CENTRAL NERVOUS SYSTEM; ERDHEIM-CHESTER DISEASE; HUMANS; KIDNEY; MALE; MYOCARDIUM; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84930824564     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.004     Document Type: Review

References (42)

1. Haroche J., Arnaud L., Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012, 24(1):53-59.
2. Haroche J., Arnaud L., Cohen-Aubart F., Hervier B., Charlotte F., Emile J.F., et al. Erdheim-Chester disease. Curr Rheumatol Rep 2014, 16(4):412.
3. Mazor R.D., Manevich-Mazor M., Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis 2013, 8:137.
4. Cavalli G., Guglielmi B., Berti A., Campochiaro C., Sabbadini M.G., Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013, 72(10):1691-1695.
5. Diamond E.L., Dagna L., Hyman D.M., Cavalli G., Janku F., Estrada-Veras J., et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014, 124(4):483-492.
6. Haroche J., Charlotte F., Arnaud L., von Deimling A., Hélias-Rodzewicz Z., Hervier B., et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012, 120(13):2700-2703.
7. Rizzo F.M., Cives M., Simone V., Silvestris F. New insights into the molecular pathogenesis of Langerhans cell histiocytosis. Oncologist 2014, 19(2):151-163.
8. Munoz J., Janku F., Cohen P.R., Kurzrock R. Erdheim-Chester Disease: characteristics and management. Mayo Clin Proc 2014, 89(7):985-996.
9. Haroche J., Cohen-Aubart F., Emile J.F., Arnaud L., Maksud P., Charlotte F., et al. Dramatic efficacy of Vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013, 121(9):1495-1500.
10. Dagna L., Corti A., Langheim S., Guglielmi B., De Cobelli F., Doglioni C., et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for treatment of patients with infliximab. J Clin Oncol 2012, 30(28):e286-e290.
11. Aouba A., Georgin-Lavialle S., Pagnoux C., Martin Silva N., Renand A., Galateau-Salle F., et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010, 116(20):4070-4076.
12. Arnaud L., Hervier B., Néel A., Hamidou M.A., Kahn J.E., Wechsler B., et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011, 117(10):2778-2782.
13. Lachenal F., Cotton F., Desmurs-Clavel H., Haroche J., Taillia H., Magy N., et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systemic review of the literature. J Neurol 2006, 253(10):1267-1277.
14. Los Arcos-Bertiz I., Santos-Ortega A., Rodriguez Palomares J., Juanos-Iborra M., Bujan-Rivas S., Tornos-Mas P., Martinez-Valle F. A 72-year-old man with dyspnea, circumferential aortic thickening, and weight loss. Arthritis Care Res (Hoboken) 2013, 65(12):2056-2061.
15. Rouco I., Arostegui J., Cánovas A., González Del Tánago J., Fernández I., Zarranz J.J. Neurological manifestations in Erdheim-Chester disease: two case reports. Neurologia 2014, (ahead of print). 10.1016/j.nrl.2014.01.010.
16. Cangi M.G., Biavasco R., Cavalli G., Grassini G., Dal-Cin E., Campochiaro C., et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 2014, 211(4):669-683.
17. Berres M.L., Lim K.P., Peters T., Price J., Takizawa H., Salmon H., et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014, 211(4):669-683.
18. Dahl G.V., Simone J.V., Hustu H.O., Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 1978, 42:2187-2192.
19. Stavem P., Evansen S.A. CNS involvement in acute myelomonoblastic leukemia. Br J Haematol 1984, 58:383-384.
20. Pinkel D., Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994, 84:355-366.
21. Creutzig U., Zimmermann M., Bourquin J.P., Dworzak M.N., Fleischhack G., von Neuhoff Sander A., et al. CNS irradiation in pediatric acute myeloid leukemia: equal results by 12 or 18Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011, 57(6):986-992.
22. Mayadev J.S., Douglas J.G., Storer B.E., Appelbaum F.R., Storb R. Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. Int J Radiat Oncol Biol Phys 2011, 80(1):193-198.
23. Sedrak P., Ketonen L., Hou P., Guha-Thakurta N., Williams M.D., Kurzrock R., et al. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011, 32(11):2126-2131.
24. Kovacs K., Bilbao J.M., Fornasier V.L., Horvath E. Pituitary pathology in Erdheim-Chester disease. Endocr Pathol 2004, 15(2):159-166.
25. Carpinteri R., Patelli I., Casanueva F.F., Giustina A. Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary. Best Pract Res Clin Endocrinol Metab 2009, 23(5):639-650.
26. Jian F., Bian L., Sun S., Yang J., Chen X., Chen Y., et al. Surgical biopsies in patients with central diabetes insipidus and thickened pituitary stalks. Endocrine 2014, 47(1):325-335.
27. Arnaud L., Malek Z., Archambaud F., Kas A., Toledano D., Drier A., et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009, 60(10):3128-3138.
28. Drier A., Haroche J., Savatovsky J., Godenèche G., Dormont D., Chiras J., et al. Cerebral, facial and orbital involvement in Erdheim-Chester disease: CT and MRI findings. Radiology 2010, 255(2):586-594.
29. Kermani T.A., Crowson C.S., Achenbach S.J., Luthra H.S. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 2011, 86(4):297-303.
30. Haroche J., Amoura Z., Dion E., Wechsler B., Costedoat-Chalumeau N., Cacoub P., et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004, 83(6):371-392.
31. Haroche J., Cluzel P., Toledano D., Montalescot G., Touitou D., Grenier P.A., et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009, 119(25):e597-e598.
32. Hervier B., Arnaud L., Charlotte F., Wechsler B., Piette J.C., Amoura Z., et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-α. Semin Arthritis Rheum 2012, 41(6):907-913.
33. Rahman M.T., Nakayama K., Rahman M., Katagiri H., Katagiri A., Ishibashi T., et al. KRAS and MAPK1 gene amplification in Type II ovarian carcinomas. Int J Mol Sci 2013, 14(7):13748-13762.
34. Madureira P., de Mello R.A. BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy. Mol Diagn Ther 2014, 18(3):285-291.
35. Andrulis M., Lehners N., Capper D., Penzel R., Heining C., Huellein J., et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013, 3(8):862-869.
36. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436(7051):720-724.
37. Kriegl L., Neumann J., Vieth M., Greten F.R., Reu S., Jung A., et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011, 24(7):1015-1022.
38. Acosta J.C., Banito A., Wuestefeld T., Georgilis A., Janich P., Morton J.P., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013, 15(8):978-990.
39. Diamond E.L., Abdel-Wahab O., Pentsova E., Borsu L., Chiu A., Teruya-Feldstein J., et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood 2013, 122(6):10.
40. Aitken S.J., Presneau N., Tirabosco R., Amary M.F., O'Donnell P., Flanagan A.M. An NRAS mutation in a case of Erdheim Chester disease. Histopathology 2015, 66(2):316-319.
41. Emile J.F., Diamond E.L., Hélias-Rodzewicz Z., Cohen-Aubart F., Charlotte F., Hyman D.M., et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014, 124(19):3016-3019.
42. Janku F., Vibat C.R., Kosco K., Holley V.R., Cabrilo G., Meric-Bernstam F., et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 2014, 5(11):3607-3610.